α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2005, Pages 217-226

  Chen, L T ^a,b,c   Liu, T W ^a   Chao, Y ^c   Shiah, H S ^a   Chang, J Y ^a   Juang, S H ^a,d   Chen, S C ^b   Chuang, T R ^a   Chin, Y H ^a   Whang Peng, J ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; THADO; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BACTERIAL PERITONITIS; BRADYCARDIA; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DROWSINESS; DRUG WITHDRAWAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LETHARGY; LIVER CELL CARCINOMA; MALE; MOUTH DISEASE; MULTIVARIATE ANALYSIS; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; WORLD HEALTH ORGANIZATION;

AGED; ALPHA-FETOPROTEINS; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 23844534451     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02547.x     Document Type: Article

References (52)

1. Prevention of Liver Cancer. WHO Technical Report Series. Geneva, Switzerland: World Health Organization, 1983: 691.
2. Lin TM, Chen CJ, Tsai SF, et al. Hepatoma in Taiwan. J Natl Public Health Assoc (ROC) 1988; 8: 91-100.
3. Chen CH, Chen DS. Hepatocellular carcinoma: 30-year experience in Taiwan. J Formos Med Assoc 1992; 91 (Suppl. 3): S187-202.
4. Lotze MT, Flickinger JC, Carr BI. Hepatobiliary neoplasms. In: DeVita, VT, Hellman, S, Rosenberg, SA, eds. Cancer: Principle and Practice of Oncology, 4th edn. Philadelphia, USA: J. B. Lippincott Company, 1993: 883-914.
5. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918-28.
6. Lai CL, Lam KC, Wong KP, et al. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981; 47: 2746-55.
7. Nerenstone S, Friedman F. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 1987; 16: 603-12.
8. Lai CL, Wu PC, Chan GCB, et al. Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma. Cancer 1988; 62: 479-83.
9. Ikeda K, Saitoh S, Tsubota A. Diagnosis and follow-up of small hepatocellular carcinoma with selective intra-arterial digital subtraction angiography. Hepatology 1993; 17: 1003-7.
10. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumour. Hepatology 1996; 23: 455-64.
11. Yamaguchi R, Yano H, Iemura A. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77.
12. Folkman J. Tumour angiogenesis: therapeutic implication. N Engl J Med 1971; 285: 1182-6.
13. Kerbe RS. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-6.
14. McBride WG. Thalidomide and congenital abnormalities. Lancet 1968; 2: 1358.
15. D'Amato RJ, Loughnan MS, Flynn E. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-5.
16. Kruse FE, Joussen AM, Rohrschneider K. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-6.
17. Figg WD, Dahut W, Duray P, et al. Randomized phase II study of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 1888-93.
18. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-15.
19. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2710-7.
20. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602.
21. Singhal S, Mehta J, Desikan R, et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
22. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2000; 98: 492-4.
23. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-65.
24. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91: 1281-7.
25. Libutti SK, Pluda JM. Antiangiogenesis: clinical applications. In: Rosenberg, SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd edn. Baltimore, MD, USA: Lippincott Williams & Wilkins, 2000: 844-64.
26. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approach needed? J Clin Oncol 2001; 19: 265-72.
27. Gradishar WJ. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials. In: Tricher, BA, ed. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ, UAA: Humana Press Inc., 2001: 341-53.
28. Chen DS, Sung JL, Sheu JC, et al. Serum α-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-9.
29. Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical applications. Gastroenterology 1985; 89: 259-66.
30. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 1980; 64: 1329-32.
31. Hsieh MY, Lu SN, Wang LY, et al. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. J Gastroenterol Hepatol 1992; 7: 614-7.
32. Rustin GL. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187s-93s.
33. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7.
34. Kanematsu M, Oliver JH, Baron RL, et al. Hepatocellular carcinoma: the role of biphasic contrast enhanced CT versus CT during arterial portography. Radiology 1997; 205: 75-80.
35. Laghi A, Iannaccone R, Rossi P, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003; 226: 543-9.
36. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
38. Cox DR. Regression model and life tables (with discussion). J R State Soc B 1972; 34: 187-200.
39. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
40. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 242-9.
41. Wang TE, Kao CR, Lin SC, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649-53.
42. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119-25.
43. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103: 749-55.
44. Wadler S. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Cancer 2005; 103: 1-4.
45. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-81.
46. Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 133-7.
47. Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumour angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185-91.
48. Kerbel RS. Tumour angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-15.
49. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
50. Slaton JW, Perrotte P, Inoue K, et al. Interferon-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-34.
51. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827-34.
52. Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome p450. Toxicol Appl Pharmacol 1986; 82: 175-9.